BREAST CANCER - NO WGD
2513 samples - 13.78 % of the cohort (P: 1378 - 54.8 % | M: 1135 - 45.2 %)
1554 samples with TP53 hits - 61.84 % (P: 805 - 51.8 % | M: 749 - 48.2 %)

NON-SMALL CELL LUNG CANCER - NO WGD
1936 samples - 10.62 % of the cohort (P: 1337 - 69.1 % | M: 599 - 30.9 %)
**1126 samples with TP53 hits - 58.16 % (P: 712 - 63.2 % | M: 414 - 36.8 %)**

COLORECTAL CANCER - NO WGD
1585 samples - 8.69 % of the cohort (P: 1193 - 75.3 % | M: 392 - 24.7 %)
1172 samples with TP53 hits - 73.94 % (P: 862 - 73.5 % | M: 310 - 26.5 %)

GLIOMA - NO WGD
1301 samples - 7.14 % of the cohort (P: 1219 - 93.7 % | M: 82 - 6.3 %)
483 samples with TP53 hits - 37.13 % (P: 455 - 94.2 % | M: 28 - 5.8 %)

PROSTATE CANCER - NO WGD

1113 samples - 6.1 % of the cohort (P: 658 - 59.1 % | M: 455 - 40.9 %)

535 samples with TP53 hits - 48.07 % (P: 283 - 52.9 % | M: 252 - 47.1 %)

PANCREATIC CANCER - NO WGD
936 samples - 5.13 % of the cohort (P: 528 - 56.4 % | M: 408 - 43.6 %)
## 697 samples with TP53 hits - 74.47 % (P: 392 - 56.2 % | M: 305 - 43.8 %)

SKIN CANCER, NON-MELANOMA - NO WGD
177 samples - 0.97 % of the cohort (P: 94 - 53.1 % | M: 83 - 46.9 %)
99 samples with TP53 hits - 55.93 % (P: 51 - 51.5 % | M: 48 - 48.5 %)

ENDOMETRIAL CANCER - NO WGD
727 samples - 3.99 % of the cohort (P: 515 - 70.8 % | M: 211 - 29.0 %)
## 312 samples with TP53 hits - 42.92 % (P: 225 - 72.1 % | M: 87 - 27.9 %)

OVARIAN CANCER - NO WGD
377 samples - 2.07 % of the cohort (P: 181 - 48.0 % | M: 196 - 52.0 %)
258 samples with TP53 hits - 68.44 % (P: 113 - 43.8 % | M: 145 - 56.2 %)

SOFT TISSUE SARCOMA - NO WGD
588 samples - 3.23 % of the cohort (P: 354 - 60.2 % | M: 234 - 39.8 %)
**225 samples with TP53 hits - 38.27 % (P: 138 - 61.3 % | M: 87 - 38.7 %)**

BLADDER CANCER - NO WGD

555 samples - 3.04 % of the cohort (P: 447 - 80.5 % | M: 108 - 19.5 %)

299 samples with TP53 hits - 53.87 % (P: 234 - 78.3 % | M: 65 - 21.7 %)

CANCER OF UNKNOWN PRIMARY - NO WGD
492 samples - 2.7 % of the cohort (P: 55 - 11.2 % | M: 437 - 88.8 %)
278 samples with TP53 hits - 56.5 % (P: 29 - 10.4 % | M: 249 - 89.6 %)

HEPATOBILIARY CANCER - NO WGD
**537 samples - 2.95 % of the cohort (P: 396 - 73.7 % | M: 141 - 26.3 %)**
264 samples with TP53 hits - 49.16 % (P: 188 - 71.2 % | M: 76 - 28.8 %)

ESOPHAGOGASTRIC CANCER - NO WGD
321 samples - 1.76 % of the cohort (P: 247 - 76.9 % | M: 74 - 23.1 %)
## 241 samples with TP53 hits - 75.08 % (P: 187 - 77.6 % | M: 54 - 22.4 %)

RENAL CELL CARCINOMA - NO WGD
508 samples - 2.79 % of the cohort (P: 347 - 68.3 % | M: 161 - 31.7 %)
169 samples with TP53 hits - 33.27 % (P: 110 - 65.1 % | M: 59 - 34.9 %)

GERM CELL TUMOR - NO WGD
92 samples - 0.5 % of the cohort (P: 62 - 67.4 % | M: 30 - 32.6 %)
39 samples with TP53 hits - 42.39 % (P: 22 - 56.4 % | M: 17 - 43.6 %)

GASTROINTESTINAL STROMAL TUMOR - NO WGD
349 samples - 1.91 % of the cohort (P: 216 - 61.9 % | M: 133 - 38.1 %)
68 samples with TP53 hits - 19.48 % (P: 30 - 44.1 % | M: 38 - 55.9 %)

THYROID CANCER - NO WGD
## 331 samples - 1.82 % of the cohort (P: 133 - 40.2 % | M: 198 - 59.8 %)
97 samples with TP53 hits - 29.31 % (P: 45 - 46.4 % | M: 52 - 53.6 %)

# HEAD AND NECK CANCER - NO WGD
271 samples - 1.49 % of the cohort (P: 118 - 43.5 % | M: 153 - 56.5 %)
## 143 samples with TP53 hits - 52.77 % (P: 69 - 48.3 % | M: 74 - 51.7 %)

NON-SMALL CELL LUNG CANCER - NO WGD
1936 samples - 10.62 % of the cohort (P: 1337 - 69.1 % | M: 599 - 30.9 %)
1126 samples with TP53 hits - 58.16 % (P: 712 - 63.2 % | M: 414 - 36.8 %)

BONE CANCER - NO WGD
150 samples - 0.82 % of the cohort (P: 86 - 57.3 % | M: 64 - 42.7 %)
67 samples with TP53 hits - 44.67 % (P: 41 - 61.2 % | M: 26 - 38.8 %)

SKIN CANCER, NON-MELANOMA - NO WGD
177 samples - 0.97 % of the cohort (P: 94 - 53.1 % | M: 83 - 46.9 %)
99 samples with TP53 hits - 55.93 % (P: 51 - 51.5 % | M: 48 - 48.5 %)

MESOTHELIOMA - NO WGD
187 samples - 1.03 % of the cohort (P: 155 - 82.9 % | M: 32 - 17.1 %)
70 samples with TP53 hits - 37.43 % (P: 55 - 78.6 % | M: 15 - 21.4 %)

SALIVARY GLAND CANCER - NO WGD
162 samples - 0.89 % of the cohort (P: 49 - 30.2 % | M: 113 - 69.8 %)
52 samples with TP53 hits - 32.1 % (P: 15 - 28.8 % | M: 37 - 71.2 %)

UTERINE SARCOMA - NO WGD
132 samples - 0.72 % of the cohort (P: 57 - 43.2 % | M: 75 - 56.8 %)
65 samples with TP53 hits - 49.24 % (P: 31 - 47.7 % | M: 34 - 52.3 %)

PERIPHERAL NERVOUS SYSTEM - NO WGD
128 samples - 0.7 % of the cohort (P: 66 - 51.6 % | M: 62 - 48.4 %)
## 40 samples with TP53 hits - 31.25 % (P: 21 - 52.5 % | M: 19 - 47.5 %)